ArticleBrain sciences2022
FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma.
Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07567196 (ResPGlioma), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data.Journal of neuro-oncology · 2025Pooled it
- Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.Journal of neuro-oncology · 2024Trial
- The STEMRI trial: Magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma stem-like cells.Science advances · 2023Trial
- Impact of 5-ALA and sodium fluorescein on FLAIR volume extent of resection and survival in IDH-wildtype glioblastoma.Journal of neuro-oncology · 2026Article
- Article
- PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target.Discover oncology · 2026Article
- Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study.Journal of neuro-oncology · 2026Article
- A voxel-based quantitative framework for analyzing the spatial redistribution and directionality of recurrence in glioblastoma.Journal of neuro-oncology · 2026Article
- Article
- Accuracy of corticospinal tract reconstruction: DTI-based deterministic versus probabilistic tractography with intraoperative validation.Frontiers in oncology · 2026Article
- Surgical decision making in the era of supramarginal glioma resections: a current perspective and narrative review.CNS oncology · 2025Review
- Segmentation-free pretherapeutic assessment of BRAF-status in pediatric low-grade gliomas.Communications medicine · 2025Article
- Extent of reoperation predicts survival in recurrent IDH-wildtype glioblastoma based on institutional data and individual patient data meta analysis.Discover oncology · 2025Article
- Preoperative FLAIR images for identifying glioblastoma boundaries.BMC medical imaging · 2025Article
- Review
- Neuroradiological Evaluation of Anatomo-Morphometric Arcuate Fascicle Modifications According to Different Brain Tumor Histotypes: An Italian Multicentric Study.Brain sciences · 2025Article
- Review
- Article
- Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.European radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard of care for isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) is maximal resection followed by chemotherapy and radiation. Studies investigating the resection of GBM have primarily focused on the contrast enhancing portion of the tumor on magnetic resonance imaging. Histopathological studies, however, have demonstrated tumor infiltration within peri-tumoral fluid-attenuated inversion recovery (FLAIR) abnormalities, which is often not resected. The histopathology of FLAIR and local recurrence patterns of GBM have prompted interest in the resection of peri-tumoral FLAIR, or FLAIRectomy. To this point, recent studies have suggested a significant survival benefit associated with safe peri-tumoral FLAIR resection. In this review, we discuss the evidence surrounding the composition of peri-tumoral FLAIR, outcomes associated with FLAIRectomy, future directions of the field, and potential implications for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.